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A Pilot Study of Intravenous Urapidil, α1-Adrenergic Blockade in the
Treatment of Severe Congestive Heart Failure
GUO-GAN WANG,1 HAO WANG,2 WENQIAO XU,2 JUN ZHU,1 YOUCHEN SONG1 AND KAM-SANG WOO3
From 1Department of Cardiology, Department of Emergency, Fuwai Heart Hospital; Cardiovascular Institute, Chinese
Academy of Medical Sciences, Peking Union of Medical College; 2Department of Echocardiography, Fuwai Heart
Hospital, Beijing, China; 3Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University
of Hong Kong, Hong Kong SAR
WANG ET AL.: A Pilot Study of Intravenous Urapidil, α 1-Adrenergic Blockade in the Treatment of Severe
Congestive Heart Failure. Objective: The aim of this study was to evaluate the efficacy and tolerability of small dose
urapidil in the treatment of patients with severe congestive heart failure. Methods: Thirty patients with severe
(NYHA class IV) congestive heart failure (male 16, female 14; mean age 55.3 ± 15.6 years) were randomly assigned
to open-labeled treatment with urapidil (Group A, 15 patients) or nitroglycerin (Group B, 15 patients). Five patients
had old myocardial infarction, 2 had essential hypertension, 22 idiopathic dilated cardiomyopathy, and one had
peripartum cardiomyopathy. Both groups were comparable in respects of age, heart rate and blood pressure. Urapidil
(100 µg/min) or nitroglycerin (20 µg/min) was administered intravenously for 24 hours in addition to conventional
treatment of heart failure (oxygen, diuretic and digitalis). Heart rate, blood pressure, blood gas and echocardiography
were measured before and after the treatment. Results: After treatment, relative changes of heart rate, diastolic
blood pressure and blood gas compared with baseline were not significantly different in both groups. However,
systolic blood pressure at 2 hours and 6 hours after treatment were lower in groups B (nitroglycerin) patients. In
group A, the left ventricular systolic parameters and stroke volume measured by echocardiography increased
significantly compared with baseline, and so were left ventricular ejection fraction and maximum flow velocity of
aortic valve. In comparison, in group B, only left ventricular ejection fraction increased and flow accelerate time of
E wave prolonged significantly. Conclusion: Small dose intravenous urapidil is a potentially useful agent in the
management of severe congestive heart failure, demonstrating a significant improvement in cardiac systolic function
and good tolerability. (J HK Coll Cardiol 2005;13:54-58)
Heart failure; Urapidil
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Introduction
Urapidil can, as an α1-adrenergic receptor
blockade, dilate peripheral small artery and reduce
the resistance of peripheral vessel by both blocking
postsynaptic α1-adrenergic receptor and central
mechanisms. 1-3 Preliminary data suggest it has
favourable blood pressure-lowering effects in
treatment of hypertensive emergencies. 3-5 Some
studies suggested urapidil could be used to treat
congestive heart failure, because it can increase
cardiac index and reduce peripheral resistance and
mean pulmonary artery wedge pressure without reflex
tachycardia. 2,6-9 This special pharmacological
property may be particularly appealing in heart failure
therapy, as use of many regimens, including
vasodilators, are often limited by the reflex
tachycardia.
The aim of this study was to evaluate the
efficacy and tolerability of small dose urapidil for
the treatment of patients with severe congestive heart
failure.

Patients and Methods
Thirty patients admitted into the Fuwai Heart
Hospital in Beijing with severe (NYHA class IV)
congestive heart failure were enrolled. Fourteen were
female and 16 were male, their mean age were 55.3±
15.6 years (range 14-76 years). The aetiology of the
congestive cardiac failure were old myocardial
infarction (in 5 patients), essential hypertension (in
2 patients), idiopathic dilated cardiomyopathy (in 22
patients) and peripartum cardiomyopathy (in 1
patient).
Inclusion criteria were as follows: Need for
intensive care treatment for acute left heart
decompensation (orthopnea with clinical and
radiological signs of severe pulmonary congestion)
in emergency ward and intensive care unit. Patient
with acute myocardial ischaemia on the basis of chest
pain, ECG and enzyme kinetics (troponins T and
creatine kinase) was excluded.
Study Protocol: Thirty patients were randomly
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assigned to open-labeled urapidil treatment (Group
A, 15 patients) or nitroglycerin (Group B, 15
patients). Intravenous urapidil, (Germany Byk
Gulden Corporation) 100 µg/min, was administered
by infusion pump for 24 hours in group A, and
intravenous nitroglycerin 20 µg/min was given by
infusion pump for 24 hours in group B. Conventional
treatments of heart failure (including inhaled oxygen,
diuretic and digitalis) were continued, except that
other vasodilators and angiotensin converting enzyme
inhibitor which were stopped temporarily. Patients
were monitored closely, and their blood pressures and
heart rate profiles at baseline and hourly intervals
after starting treatment, as well as clinical features
including severity of dyspnoea symptom and
echocardiographic profiles at baseline and 24 hours
after treatment in the 2 groups were compared. Any
adverse reactions during the infusion treatment were
recorded.
Echocardiography parameters include: left
ventricular diastolic end diameter (LVEDd), left
ventricular stroke volume (SV), and left ventricular
eject fraction (EF%) measured by 2D-guided MMode, maximum flow velocity of aortic valve
(AoVmax), flow accelerate time of aortic valve
(AoVact) and flow shift parameters measured by
standard Doppler echocardiographic technique.
Statistical analysis: Changes in blood pressure
and echocardiographic parameters were tested for
significance using the Student's t test for paired
samples. A probability level of P<0.05 was
considered significant for the study.

Results
The 2 groups were comparable in the baseline
clinical and echocardiographic diameters (Table 1).
Changes in clinical parameters: There were no
significant changes in heart rate and diastolic blood
pressure after treatment in both groups. However, the
systolic blood pressure at 2 hours and 6 hours after
treatment were significantly lower in group B but not
in group A patients (see Figure 1).
Some patients in both groups receive inotrope
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Table 1. Clinical features of 2 groups at baseline
Age (year)
SBP (mm)
DBP (mm)
Heart Rate (beats/min)
CAD
HHD
DCM
LVEF (%)

Urapidil group (n=15)
55.8±16.7
115.6±12.3
70.1±8.6
89.2±9.1
3
1
11
22.1±3.6

Nitroglycemia group (n=15)
54.8±14.6
114.1±18.9
69.8±8.5
89.4±8.9
2
1
11
25.6±2.4

p-value
NS
NS
NS
NS
NS
NS
NS
NS

CAD: coronary artery disease; DCM: dilated cardiomyopathy; DBP: diastolic blood pressure; HHD: hypertensive heart disease; LVEF: left
ventricular ejection fraction; NS: not significant; SBP: systolic blood pressure

Figure 1. Changes in systolic blood pressure in both groups. The systolic blood pressures
at 2h and 6h after treatment were lower significantly in group B (nitroglycerin) patients
but not in group A (urapidil) patients. *P<0.05 vs before treatment.

treatment (8 dopamine, 5 milrinone, 3 amrinoone in
group A; and 8 dopamine, 7 milrinone, 2 amrinoone
in group B respectively) in addition to digitalis after
24 hours admission.
Clinical symptoms improved after treatment in
both patient groups. There were no adverse drug
reaction present, with no dizziness, palpitation, nor
nausea, but one group B patient developed transient
atrial fibrillation.
During hospital, there are two patients occurring

J HK Coll Cardiol, Vol 13

atrial fibrillation and one patient with multifocal
premature ventricular complexes in group A. However,
in both groups, no any patient received mechanical
ventilation and died in hospital. There are no significant
different in duration of ICU and in hospital between
group A and group B (7.0±2.5, 8.3±3.5, p=0.18;
14.3±7.8, 17.7±6.6, p=0.08, respectively).
Changes in cardiac function parameters: In
group A, the stroke volume increased significantly
compared with baseline (57.7 vs 70.9 ml, p<0.01),

October 2005

56

HEART FAILURE MANAGEMENT

vascular resistance, reduction in tissue purfusion,
retention of sodium and water and cardiac failure
deterioration.
During past decades, vasodilators have been
developed, which have been proven a major advance
in the treatment of heart failure, in decreasing the
preload and afterload of the heart, with subsequent
curative effect. Studies have documented that they
were well tolerated and effective in improving heart
failure symptoms.6,9
Nitroglycerin can, as predominantly a
venodilator, reduce blood volume return to heart
leading to a decrease preload of heart, but relatively
little effect on resistance of peripheral vessel and
cardiac output.6
This study results show that there were
no improvement in LVEDd and SV 24 hours
after infusion nitroglycerin, but an increase in EF%
(16%) which however was less than in group A
(33.8%).
Urapidil is a new antihypertensive agent with
unique properties initially designed for the treatment

and so were ejection fraction and AoVmax (22.1% vs
29.7%, p<0.01 and 0.89 m/s vs 1.04 m/s, p<0.05
respectively) (see table). In group B, only ejection
fraction increased significantly (25.6% vs 29.7%,
p<0.01), while flow decelerate of E wave (E dct) were
significantly prolonged (108.9 ms vs 125.0 ms,
p<0.01) (Table 2).
Blood gas parameters: There were no
significant changes in blood gas parameters after
treatment in the two groups.

Discussion
It is well known that low cardiac output,
excessive blood pooling in venous circulation and
increase peripheral vascular resistance are the
principal haemodynamic alterations in congestive
heart failure. In this process, neurohumoral
activation (autonomic nervous system and reninangiotensin-aldosterone systems) takes place, 6
resulting in increase in heart rate and systemic

Table 2. Changes in echocardiographic parameters in both groups

LVEDd (cm)
FS%
EF%
SV (ml)
AoVmax (m/s)
AoVact (ms)
E act (ms)
E dct (ms)
E et (ms)
TVI
VmaxE (m/s)
VmaxA (m/s)
E/A

Before
7.2±0.8
14.5±1.9
22.1±3.6
57.7±8.7
0.89±0.09
84.5±8.2
62.3±9.1
118.7±11.2
181.6±13.1
9.8±1.6
0.87±0.16
0.28±0.18
3.4±0.9

Urapidil
After
7.0±0.9
14.2±1.8
29.7±4.1
70.9±7.8
1.04±0.07
84.3±7.9
70.4±8.9
124.2±12.1
193.9±14.2
9.4±1.5
0.81±0.19
0.32±0.20
3.0±0.8

P
NS
NS
<0.01
<0.01
<0.05
NS
NS
NS
NS
NS
NS
NS
NS

Before
7.0±0.8
14.0±1.9
25.6±2.4
58.7±8.9
0.91±0.10
78.8±8.6
69.8±8.9
108.9±9.2
178.7±0.1
10.6±1.9
0.84±0.18
0.49±0.21
1.6±0.8

Nitroglycerin
After
6.9±0.9
13.0±1.8
29.7±2.5
65.3±8.8
0.9±0.11
84.7±8.1
69.3±7.9
125.0±7.9
194.8±26.6
9.8±1.8
0.82±0.17
0.62±0.22
1.6±0.7

P
NS
NS
<0.01
NS
NS
NS
NS
<0.01
NS
NS
NS
NS
NS

LVEDd: left ventricular diastolic end diameter, FS%: percentage of fractional shortening, EF%: left ventricular eject fraction, SV: left ventricular
stroke volume, AoVmax: max flow velocity of aortic valve, AoVact: flow accelerate time of aortic valve, E act: flow accelerate time of E wave,
E dct: flow decelerate time of E wave, E et: flow time of E wave, TVI: integral of tricuspid valve flow, VmaxE: max flow velocity of E wave,
VmaxA: max flow velocity of A wave, E/A: ratio of E wave and A wave.
* Expressed as mean ± SD
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of hypertension. 3-5 It decreases peripheral vascular
resistance by postsynaptic alpha l-blockade, reduction
of the central sympathetic tone and inhibition of the
pressor baroreceptor reflexes. 1-4 These result in
reduction of peripheral vessel resistance, afterload
and elevation in cardiac output.1-4 In addition, some
data suggest urapidil therapy and independent of
nitric oxide involvement, decreases high circulating
levels of endothelin within hours and restore
physiological balance across pulmonary, coronary,
and peripheral vascular beds,10 without affecting the
sodium excretory capacity of kidney. 11
In this regard, after urapidil infusion, among
the cardiac systolic indices, SV, AoVmax and EF%
in particular increased significantly compared to
baseline, documenting an improvement in pump
function of the heart.
Some previous literature proposed
congestive heart failure be treated by continuous
infusion of urapidil following a bolus dose. 1-3,7,8
However, a bolus dosage of intravenous urapidil
given within a short time could cause hypotension
and even shock, as the blood pressure is already
usually lower in patients with congestion heart
failure. There were no hypotension occurring
using a small dosage (100 µg/min) of urapidil by
continuous infusion for 24 hour without a bolus
dose in the present study.
In addition to its peripheral effects, urapidil
could reduce central sympathetic nervous activity via
stimulation of serotoninergic 5-hydroxytryptamine
1A receptors in medulla oblongata and affect the
baroreceptor reflex, which may explain the lack of
reflex tachycardia. Based on these properties, urapidil
may have some advantages over other agents used in
acute decompensated heart failure. In this context,
specifically urapidil can be used to treat congestive
heart failure from ischaemia heart disease in
particular,4,7 as well as in hypertensive and idiopathic
dilated cardiomyopathy, as it can avoid the potential
risk of cardiac ischaemia due to reflex heart rate
increase.

J HK Coll Cardiol, Vol 13

Conclusion
Small dose continuous intravenous urapidil
infusion is a potentially useful agent in the
management of severe congestive heart failure, with
significant improvement in cardiac systolic function
and good tolerability.
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Tachycardia Amongst Subjects Recovering from Severe Acute
Respiratory Syndrome (SARS): A Prospective Case Study
SUET-TING LAU, 1 WAI-CHO YU, 1 NGAI-SHING MOK, 1 PING-TIM TSUI, 1 WING-LOK TONG, 1
STELLA WAI-CHEE CHENG2
From 1Department of Medicine & Geriatrics; 2Occupational Therapy Department, Princess Margaret Hospital,
Lai Chi Kok, Hong Kong SAR
LAU ET AL.: Tachycardia Amongst Subjects Recovering from Severe Acute Respiratory Syndrome (SARS):
A Prospective Case Study. Background: SARS is a new infection in humans with unknown medium or long-term
complication. Palpitation in the form of tachycardia is common amongst patients recovering from SARS. We studied
the extent and possible cause of tachycardia in these patients. Methods: Prospective cross-sectional case series of
patients treated in Princess Margaret Hospital in Hong Kong recovering from SARS who had resting heart rate of
more than 90 beats per minute (BPM) at follow up about 2 months from onset of illness was recruited for assessment
of heart rate and rhythm, cardiac function, pulmonary function, laboratory tests, Quality of Life score and Functional
assessment. Patients were followed up in the out-patient clinic for at least 1 year after discharge. Results: Fifteen out
of 100 consecutive patients were eligible for study. Median mean heart rate was 82 BPM (range 70-91) with maximum
heart rate ranging from 114 to 163 BPM. Sinus tachycardia was recorded only in daytime. Signal average ECG,
heart rate variability, and echocardiography were normal. Two patients had significantly impaired spirometic indices
while all but one had normal diffusion capacity study. Mean haemoglobin level was 13.4 gm/l (10.6-14.9). Troponin
I, thyroid function, arterial blood gases, C reactive protein and liver function tests were normal. Quality of Life
(QOL) score was low especially in the psychological well being domain. Monitored Functional Task Evaluation
(MFTE) score demonstrated mild functional difficulties in 10 patients (score17.6-19.7). No symptom of palpitation
was present at follow up after 1 year. Conclusion: No significant arrhythmia or cardiac abnormality was identified.
Sinus tachycardia on exertion in patients recovering from SARS is possibly attributed to physical deconditioning and
contributed by psychological impairment. (J HK Coll Cardiol 2005;13:59-67)
Severe Acute Respiratory Syndrome, Tachycardia

SARS

SARS
SARS

114
14.9

163

100

10

15

90
82

70-91
13.4 gm/l

C

17.6-19.7

10.6-

SARS

Address for reprints: Dr. Suet-Ting Lau
Department of Medicine & Geriatrics, Princess Margaret Hospital,
Lai Chi Kok, Kowloon, Hong Kong
Tel: (852) 2990 3581; Fax: (852) 2990 3148
Received September 15, 2005; revision accepted October 22, 2005

59

October 2005

J HK Coll Cardiol, Vol 13

LAU ET AL.

Introduction
SARS is a severe, readily transmissible disease
caused by a novel coronavirus.1,2 It emerged in midNovember 2002 in Mainland China and Hong Kong
became affected in March 2003.3 By late June 2003 there
were 8,439 cases worldwide and 1,755 cases in Hong
Kong, the latter being one of the hardest hit areas.4 While
the presenting features and acute clinical course has been
well studied,5-8 whether there are medium to long-term
complications remain unknown. Princess Margaret
Hospital (PMH) had managed 585 confirmed cases up
to end of June, 2003. At follow up visits patients
complained of palpitation in the form of fast heart beat
and a resting rate of over 90 beats per minute (BPM)
was not uncommon among them. Such patients may
experience palpitation at rest and this became marked
during mild exertion, often with associated shortness
of breath. 12 lead ECG showed sinus tachycardia.
Possible causes are deconditioning, 9 impaired
pulmonary function, impaired cardiac function, cardiac
arrhythmia, thyroid dysfunction, anaemia, autonomic
dysfunction10,11 and anxiety state. This case study aims
at finding out the extent of tachycardia, the likely
explanation(s) for the tachycardia and the condition after
1 year.

Methods
This is a prospective cross-sectional case series
study involving SARS patients treated in PMH in Hong
Kong − a district hospital designated to treat SARS
patients during the outbreak in March 2003. All patients
were offered pulmonary function tests including
spirometric and diffusion studies at follow up around 2
months from onset of illness. Blood pressure and resting
heart rate after sitting for 10 minutes were checked
before the tests. Subjects with sitting heart rate ≥90 BPM
out of the first 100 consecutive patients were recruited
into the study. Written informed consent was obtained.
The following laboratory investigations were
done at recruitment: Arterial blood gases (ABG),
c o m p l e t e b l o o d p i c t u r e ( C B P ) , e r y t h r o cy t e

J HK Coll Cardiol, Vol 13

sedimentation rate (ESR), liver function tests (LFT),
free-thyroxin (FT4), thyroid stimulating hormone
(TSH), lactate dehydrogenase (LDH), creatine kinase
(CK), troponin-I, C-reactive protein (CRP).
Quality of life (QOL) assessment and functional
assessment were done at the same hospital visit. For
QOL assessment, we employed World Health
Organization (WHO) QOL-BREF 12 that is an
abbreviated version of the WHO QOL-100. The
questionnaire has been translated into Chinese and
validated locally (WHO QOL-BREF Hong Kongunpublished data) and it encompasses 4 life domains
including physical health, psychological well being,
social interaction and environmental aspects. The tool
for functional assessment was the Monitored Functional
Task Evaluation (MFTE)13 developed in Hong Kong and
adopted by the Occupational Therapists Committee
in Hospital Authority Hong Kong for the SARS
Rehabilitation Programme. The QOL questionnaire and
METE are attached as Appendix.
The following cardiac investigations were
completed within 1 week of recruitment: 12-lead
ECG at rest, signal average ECG (SAECG), Holter
monitoring with heart rate variabililty (HRV) using time
domain analysis, and echocardiography including Mmode, 2-D and colour Doppler studies.
Patients were offered the Rehabilitation
programme on voluntary basis and regularly followed
up at 3 month intervals for more than 1 year after
discharge.
The Ethics Committee of the Kowloon West
Cluster of the Hong Kong Hospital Authority approved
the study.

Results
Fifteen consecutive patients complied with the
inclusion criteria were recruited amongst the initial 100
patients attending the lung function test. There were
8 male and 7 female patients, aged from 25 to 62 (mean
34.4). All patients had at least 4-fold rise (<25/2001600) in SARS-coronavirus antibody titre. The resting
12-lead ECGs showed a sinus heart rate ranged 90 to
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109 BPM. They were normal, except in patient 4 who
had a partial right bundle-branch block. Holter
monitoring demonstrated a mean heart rate of 82.3 BPM
(range 70-91, SD 5.05) with maximum heart rates of
114-163 BPM. Eleven patients had sinus tachycardia
of more than 130 BPM (Table 1). Overall heart rate
more than 100 BPM was observed during the day time
(9:00am to 9:00pm) but not at night. No other
arrhythmia was detected. Heart rate variability using
the time domain analysis showed that the Standard
deviation of all normal RR interval (SDNN) was normal
(SDNN >100 ms in patients <60 years of age and 97
ms in the 62 year old patient) (Table 1). SAECG was
within normal criteria in all subjects. Echocardiography
revealed no abnormality apart from the 62-year-old
patient who had mild diastolic dysfunction.
Eight patients had normal spirometric indices,
5 had mild impairment and 2 had moderate to severe
impairment. Carbon monoxide diffusing capacity was
normal for all but patient 4 who also had mild
spirometric and restrictive defect (Table 2).

Chest X-ray at follow-up was normal in
5 patients and abnormal in 10. The latter group included
the 2 patients with moderate to severe spirometric
impairment and some, but not all, patients with mild
spirometric impairment.
Mean haemoglobin level was 13.4 gm/l (range
10.6-14.9). White cell counts, ESR, LDH, CK, troponin
I, thyroid function tests, arterial blood gases, C-reactive
protein and LFTs were normal. The length of hospital
stay varied from 18 to 54 days and the period after
discharge varied from 14 to 51 days (Table 3). Most
patients also had complications that could account for
a protracted course of illness and impaired recovery
(Table 3). No specific complication was identified in
Patient 11 who was aged 62, the eldest patient in this
cohort.
The QOL domain score was impaired (score <75)
in 11/15 in physical health, 13/15 in psychological well
being, 9/15 in social interaction and 11/15 in
environmental aspects. Severe impairment with a score
of ≤50 occurred in six patients in the psychological well

Table 1. Holter monitoring results
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

Sex

Age

Min HR

Max HR

Mean HR

HR Variability SDNN (ms, N>100 ms)

M
F
F
M
F
F
M
M
F
F
M
M
F
M
M

25
30
25
40
34
28
33
49
26
39
62
36
25
26
47

50
46
47
52
61
53
50
51
49
51
53
57
55
54
50

141
154
153
136
152
145
137
142
129
116
114
123
163
147
135

87
77
84
82
85
91
87
83
77
79
70
83
85
83
82

133
181
167
131
104
123
118
137
135
103
97
111
147
122
140

Age = Age in years; Min HR = Minimum heart rate beats per minute; Max HR = Maximum heart rate beats per minute; SDNN = Standard
deviation mean RR interval
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Table 2. Pulmonary function testing
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

FVC FEV

Flow rates

Lung volume

DLCO

Interpretation

N
N
Low
Low
Low
Low
Low
N
Low
N
N
N
N
Low
N

Low
N
Low
N
Low
Low
Low
N
Low
N
Low
N
N
Low
N

N
N
Decreased
Increased
N
Low
Low
Increased
N
Increased
Increased
N
N
Decreased
N

N
N
N
N
N
N
Low
N
N
N
N
N

Normal
Normal
Restrictive moderate
Obstructive very mild
Restrictive mild
Restrictive severe
Restrictive mild
Normal
Normal
Normal
Obstructive mild
Normal
Normal
Restrictive very mild
Normal

N
N

FVC = Force Vital Capacity; FEC = Force Expiratory Volume; DLCO = Diffusing Capacity for Carbon Monoxide

Table 3. Other factors
CXR finding

Hb

LOS

Discharge to PFT

Complication

1
2
3
4
5
6
7
8
9
10

Mottling RLZ
N
Bilat shadowing
N
Bilat lower zone hazziness
Bilat lower zone hazziness
Bilat middle zone hazziness
Mild hazziness RLZ, LMZ
N
Bilat lower zone hazziness

13
12.8
13.3
14.5
12.8
12.9
14.1
13.1
13.9
10.6

35
25
54
37
30
39
35
21
24
31

31
36
21
14
18
23
21
51
33
18

AD
AD
SP, CI
Pne
ICU
ICU
ICU
AD
AD
UTI

11
12
13
14
15

N
Bilat diffuse hazziness
N
Bilat M&LZ hazziness
Bilat lower zone hazziness

12.6
14.6
13.6
14.9
13.5

18
21
21
25
29

34
45
21
23
29

CI
CI
ITP
ICU

Hb = Haemoglobin in g/dl; LOS = Length of hospital stay in days; Discharge to PFT = Discharge to day of pulmonary function test in days;
ICU = ICU Care; ITP = Idiopathic thrombocytopenic purpura; UTI = Urinary tract infection; CI = Chest infection; AD = Anxiety depression; SP
= Steroid psychosis; Pne = Pneumomediastinum and subcutaneous emphysema
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being domain. MFTE score was less than 20 (range
17.6 -19.7) in 10 patients indicating the presence of mild
functional difficulties (Table 4).
All patients were regularly followed up and no
medication that could cause tachycardia was given.
Eleven of the 15 patients joined the rehabilitation
programme of the hospital. All patients were followed
up for 12 to 20 months after discharge. Patient 9 had a
low score in the social relationship score (50), low
MFTE score (19.6) and declined rehabilitation. She had
anxiety, poor sleep and occasional forceful palpitation
and repeated Holter monitoring at the 1 year follow up
showed normal finding. The rest of the patients had no
symptom of palpitation or dypsnoea at the follow up at
12 to 20 months.

Despite having been hospitalized for 18 to 54 days and
discharged for 14 to 51 days, physical function recovery
was not satisfactory for patients in this cohort. The
medium and long-term complications of SARS remain
unknown resulting in uncertainty and anxiety. Some
patients refrained from getting more physically active
for fear of causing deterioration. Assessment of this
cohort of patient to identify ongoing disease activity,
pulmonary function impairment, evidence of
myocarditis and psychological impact was warranted.
The investigations were targeted at determining the
extent of tachycardia and possible explanation(s). The
major symptom was palpitation on slight exertion.
Patients with resting heart rate at greater than 90 BPM
were recruited because they are expected to have
tachycardia response to greater than 100 BPM.
Patients with SARS had lymphopenia, anaemia,
raised LDH and CRP at the acute stage.6 The normal
CBP, ESR, LFT, LDH, CK, CRP, as well as results of
clinical assessment, suggest that ongoing active disease
is unlikely. One patient had iron deficiency anaemia

Discussion
Palpitation at about 2 months after onset of illness
raised concern for both the clinician and the patient.

Table 4. Questionnaire
Physical Health
Domain
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

75
*44
69
56
75
88
63
69
63
63
63
75
55
69
63

QOL
Psychological Health Social Relationship
Domain
Domain
I
II
63
*50
69
*44
75
81
75
63
56
56
*50
63
*50
*50
*25

69
*50
75
*50
75
81
75
63
56
63
*50
63
56
56
*38

50
56
100
56
81
81
75
69
50
75
56
56
69
56
56

Environment
Domain

MFTE

Rehabilitation
Programme

75
50
75
56
81
69
88
63
69
63
50
69
56
69
56

20
20
19.4
19.7
18.8
19.5
18.7
20
19.6
20
18.8
19.8
17.6
20
19.2

Y
Y
Y
Y
Y
Y
Y
N
Y
Y
N
N
Y
N
N

QOL = Quality of Life Score; MFTE = Monitoring Functional Task Evaluation; *=Score ≤50
QOL score - Normal >75; MFTE score - Normal >20; Rehabilitation Programme Y = Yes, N = No
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with a haemoglobin level of 10.6 g/dl that was similar
at presentation. Normal thyroid function excluded
thyrotoxicosis as the cause.
Coronarvirus infection had been demonstrated in
animal model to cause an autoimmune myocarditis in
rabbits that may progress to dilated cardiomyopathy.14-16
Li et al reported reversible subclinical diastolic
dysfunction without systolic impairment in the acute
stage.17 In our study, non-invasive cardiac investigations
were done to document the extent of tachycardia and
any significant cardiac complication. Holter monitoring
demonstrated a minimal heart rate of 46 to 61 BPM
and the sinus tachycardia at a rate of 114 to 163 BPM
occurred in the daytime but not at night. Analysis of
overall heart rate ≥100 BPM for each hour demonstrated
occurrence between 9.00am to 9.00pm. in the
awakening hours. This pattern of tachycardia is in
keeping with physical deconditioning or anxiety state
as the underlying cause, in response to physical
activity or psychological stress. The normal SDNN
in heart rate var iability indica ted a normal
neurohumoral profile and excluded autonomic
dysfunction.18,19 No significant arrhythmia detected
in the Holter monitoring in addition to the normal
12 lead ECG and SAECG signify a low risk of
arrhythmia. 20 Normal troponin I, echocardiography
and other negative cardiac investigations excluded
myocarditis and cardiomyopathy.21,22
Residual pulmonary defect is another major
concern. Residual CXR changes were mild and the
pulmonary function impairment were not marked. These
together with a normal blood gas would be unlikely to
be a significant cause of sinus tachycardia with normal
activity.
SARS is a new disease characterized by its highly
contagious nature and severe pulmonary involvement
with a 20% ICU admission rate. Our cohort of patients
had a length of hospital stay ranging from 18 to 54 days,
and they were advised to take infection precautions for
another 14 days after discharge from hospital. The
impact of this severe viral infection together with
confinement would lead to physical deconditioning
resulting in increased magnitude of tachycardia and
decreased exercise tolerance. In addition, this cohort of
patients had a more severe form of disease or various

J HK Coll Cardiol, Vol 13

complications that caused prolonged hospitalization and
hampered recovery. Four patients required ICU
admission; 3 had secondary chest infection; one had
urinary tract infection; one had idiopathic
thrombocytopenia; one had pneumomediastinum and
subcutaneous emphysema; one had steroid psychosis
and 4 had anxiety depression. Patient 11 aged 62 is the
eldest patient among this series combatable with a more
protracted course of illness in the elderly. He had mild
diastolic function that is quite common in patients with
hypertension and gout. He did not have other identified
complication at the acute stage.
All patients were treated with a protocol
c o n s i s t i n g o f a n t i m i c ro b i a l s , r i b av i r i n a n d
hydrocortisone or methylprednisolone, in accordance
with the guidelines issued by the Hong Kong Hospital
Authority in April/May 2003.23 Systemic steroid in the
form of hydrocortisone or methyl prednisolone was
prescribed for all patients, with high dose (pulsed)
methyl-prednisolone given to 13 patients. All 15 patients
had some degree of subjective proximal muscle
weakness and this may contribute to impaired physical
fitness. All patients did not have medications causing
tachycardia at time of assessment.
All patients also received the antiviral agent
ribavirin. High dose administration of this drug can
cause bradycardia that was reversible on stopping the
drug,24,25 as observed in patient 6 in the cohort. However,
there was no report of prolonged cardiotoxicity due to
ribavirin. Additionally, ribavirin causes haemolytic
anaemia in a high proportion of cases, and rapid onset
of anaemia can cause tachycardia. Such haemolytic
anaemia is usually quickly reversible and all patients in
the cohort had haemoglobin at pre-illness levels by the
time they were recruited into the study.
Subjective impairment of physical health,
psychological well being and functional disability were
evidenced by the high proportion of subjects with low
QOL and MFTE scores. In fact, all patients had
abnormal score in either one of these assessments.
Severe impairment was predominant in the
psychological well being domain. Anxiety state can be
a cause of tachycardia in the daytime but not at night
compatible with the pattern observed in the studied
patients.
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Furthermore, tachycardia, impairment of physical
health, and impairment of psychological well being may
all stem from severe physical deconditioning. The
patients were offered a rehabilitation program conducted
by the physiotherapy and occupational therapy
departments of the hospital in out patient setting.
Regular follow up at intervals of 1 to 3 months in the
out-patient clinic as other post SARS patients to observe
their progress was done. Observation for 12 to 20
months after discharge did not reveal significant cardiac
symptom. Only 1 patient had complained of occasional
palpitation with forceful heartbeat and requested further
investigation. Repeated blood tests and Holter
monitoring were normal.

Conclusion
SARS is a severe systemic illness causing
physical and psychological impairment in patients up
to 2 months from onset of illness. In the absence of
significant dysfunction of the cardiac, pulmonary,
thyroid and haematological systems, sinus tachycardia
on exertion is possibly attributable to physical
deconditioning. In addition poor psychological state is
likely to be a contributing factor. After appropriate
rehabilitation programmes and follow up observations,
no other suggested cause of tachycardia in the post
SARS patients could be elucidated.
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control of SARS patients with no tachycardia. The
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impairments and whether functional impairment was
in fact contributed by steroid myopathy. Additionally,
cardiopulmonary exercise testing would have provided
data on exercise tolerance, oxygen consumption
and anaerobic threshold, and would give a more
comprehensive picture of the pathophysiology involved.
The study was terminated because of the negative
findings. Further cardiac investigations reassessment
was not done because of the negative findings and
further repeated investigations would poise undue stress
and anxiety in the patients who were having immense
medical and public attention. Only routine follow up as
the other patients were done in the clinic.
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Appendix (con't)
Occupational Therapy
SARS Patient Evaluation
Princess Margaret Hospital

Please Use Block Letter or Affix Label
Name : _________________ (
Sex / age : ______ Ward / Bed :

)

Monitored Functional Task Evaluation/ADL Checklist
Date :
Resting SaO2 / Pulse : ____ % /____
Oxygen Desaturation : heavy / moderate / mild
Dyspnea (Max) : ____ / 10 Exertion (Max) : ____ /10 Tiredness (Max) : ___ /10 Total marks: ____ /20

Task
2 mins completed
Duration
Number / 2 mins
Pace
RPD / RPE / RPT
Recovery
SaO2
Pulse Rate
Marks

1
Indoor Mobility
yes / no
:
even / rush
/ /
2 mins /
%

2
Lifting 3 kg
yes / no
:
even / rush
/ /
2 mins /
%

Lift role : ____ Premorbid ADL level : ____ (marks
ADL level
Level 1

Level 2

Level 3

Level 4

Level 5

67

Activity
resting on chair / watching TV
feeding
grooming (e.g. wringing towel / shaving)
managing bowel
transfers to / from bed
dressing garments
dressing shoes / socks
indoor mobility
bathing (shower / basin / bathtub)
washing hair
simple households (e.g. washing utensils)
simple cooking (e.g. rice-cooker)
walking up one flight of stairs
strolling for 20 mins
complex households (e.g. bedmaking)
complex cooking (e.g. frying)
laundry / ironing
shopping (carrying 61bs for 15 mins)
public transport (taxi / bus) by self
heavy households (e.g. mopping floor)

3
Stepping
yes / no
:
even / rush
/ /
2 mins /
%

4
Carrying 6 kg
Yes / no
:
even / rush
/ /
2 mins /
%

); Present ADL level : ____ (marks
Premorbid

5
Sit<=>Stand
yes / no
:
even / rush
/ /
2 mins /
%

)

Present

Marks
1
2
3
4
5
6
7
8
9
10
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A Systematic Review on the Role of Diet and Nutritional Supplements
for Prevention of Cardiovascular Diseases
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Hong Kong SAR
CHAN ET AL.: A Systematic Review on the Role of Diet and Nutritional Supplements for Prevention of
Cardiovascular Diseases. According to the diet-heart hypothesis, dietary factors play a pivotal role in atherogenesis.
Modulation of the diet has therefore been considered a means to achieve better cardiovascular health and a major
subject of public health importance. Five major types of diet have been identified: the low-carbohydrate diet, low
glycemic index diet, very-low-fat diet, the Mediterranean diet and the Dietary Approaches to Stop Hypertension
(DASH) diet. Clinical studies have shown that none of these diets are universally efficacious. The results from various
clinical trials on the use of diet to prevent cardiovascular diseases are commonly conflicting due to unadjusted
caloric intake and concurrent changes in alternative food consumption. Nonetheless, a diet rich in fresh fruits and
vegetables with polyunsaturated fat intake from plant oil and fish, but restricted intake of high glycemic index
carbohydrates is generally advisable. The importance of an individualized approach and holistic lifestyle commitments
including regular exercise should be emphasized. Currently, there is limited data on nutritional supplements in heart
health. Recent clinical trials have shown that vitamins C and E supplement are ineffective, and the use of high dose
vitamin B and folate is actually harmful. Physicians should therefore be cautious in advising on and prescribing
these supplements. Phytoestrogen represents a recently focused branch of nutritional supplement with potentially
cardioprotective implications. Its recommendations should depend upon further randomized controlled trials. (J HK
Coll Cardiol 2005;13:68-84)
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Introduction
Although the role of diet in atherogenesis has
been questioned for nearly a century, a large part of
this question remains unanswered today. The role of
diet in both prevention and management of coronary
artery disease (CAD) remained inconclusive and highly
controversial. Current nutritional thoughts have been
dominated with the traditional diet-heart hypothesis,1-3
which is characterized by the causal relationships
between serum cholesterol elevation and atherosclerotic
heart diseases as a consequence to dietary intake of
saturated fat (Figure 1). This philosophy has led to the
most unparalleled dietary recommendation ever: that a
low-fat diet is heart-healthy and preventive against
cardiovascular diseases. For instance, the latest
guideline of American Heart Association in 2000
recommends a low-fat diet in which 55% of total
calories is derived from carbohydrates, 30% from fat,
the remaining 15% from proteins, with cholesterol not
exceeding 300 mg per day. 4 However, this dietary
recommendation has resulted in a paradoxical uprising
trend of Type II diabetes, obesity and metabolic
syndrome in the developed world.1 The prevalence of
obesity in the United States had surged new heights and
increased by more than 60% in ten years since 1991.5

This epidemic of obesity and related syndromes could
simply be a result of unrestricted carbohydrate intake,
which was indirectly promoted by a low-fat diet.

Diet and Cardiovascular Diseases
With this increasing frustration and the realistic
eagerness of the population to find alternative ways of
effective slimming, the diet-heart hypothesis could no
longer stay unshaken. Both scientists and dieticians thus
have started to explore other dietary approaches in heart
health, the best noted categories include: 1) lowcarbohydrate diet; 2) low Glycemic Index (GI) diet;
3) very-low-fat diet; 4) the Mediterranean diet; and
5) the Dietary Approaches to Stop Hypertension
(DASH) diet. Table 1 summarizes the current status of
different diets used for heart health, and other factors
such as personal lifestyle and preference that will also
affect their efficacy and sustainability at different time
and places. It is thus unrealistic to expect there could
ever be a single diet, which could serve the purpose of
everyone. Generalized dietary approaches to
cardiovascular heath, however, could be extracted with
the available evidence and are summarized in Table 2.
Indeed, the US Department of Agriculture has recently

Figure 1. The diet-heart hypothesis. The conventional diet-heart hypothesis is essenced by a
syllogism of dietary saturated fat intake, serum cholesterol and atherosclerosis. It has however
remained controversial and is now increasingly questioned due to the emerging role of
polyunsaturated fatty acids as a component of dietary fat which may potentially confer
cardiovascular benefits.
69

October 2005

J HK Coll Cardiol, Vol 13

CHAN ET AL.

Table 1. Summary on the characteristics of the major types of diets
Type of diet
Atkins' Diet

Low GI diet

Composition
68% fat, 27% protein,
5% carbohydrates;
extreme carbohydrate restriction in
the first 2 weeks
Complex carbohydrates in
preference to simple sugars

Very-low-fat diet

<15% fat,
15 % protein,
70% carbohydrates

Mediterranean diet

High consumption of fruits,
vegetables, legumes & grains;
foods with high monosaturated/
saturated fats ratio;
moderate dairy products & wine
consumption; reduce meat
consumption; high intake of
Omega-3 fatty acids
Similar to Mediterranean diet;
high in potassium, calcium,
magnesium and fiber

DASH

Current knowledge
Short-term weight loss;
Sustained improvements in lipid profile
at 1 year;
Unknown long-term effects
Low GI confers to greater weight loss;
Unknown effects in cardiovascular
diseases;
Possible negative association with
diabetes
Possible reduction in cardiac event risk;
Intensive life-style changes often
corporated;
Self-motivation & sustainability strongly
required
Secondary prevention of acute & fatal
myocardial infarction;
Reduction of sudden cardiac deathby its
anti-arrhythmic effects;
Unknown effects of mercury exposure

Reduced both systolic and diastolic
blood pressure; greatest effect among
African, Americans and hypertensive
individuals

Sustainability
Low to moderate

Moderate to high

Low

High

Moderate to high

Table 2. Summary of healthy dietary approaches
Generalized approaches to a healthier diet:
↓
Carbohydrate intake (Refined and high GI carbohydrates)
↑
Consumption of fruits, vegetables & whole grains
↑
Polyunsaturated fat intake from plants oils & fish
→ Moderate intake of low-fat dairy products & nuts
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announced a new food pyramid - My Pyramid which
emphasizes the need of individualized approaches and
the element of exercise in promoting heart health
through lifestyle changes (Figure 2).

Low-carbohydrate Diets
There are numerous forms of low-carbohydrate
diets such as the Zone Diet, Protein Power, Sugar
Busters and the Stillman Diet, but the Atkins' Diet
remains the most popular variant in recent years. The
Atkin's Diet recommends vigorous carbohydrate
restriction, regardless of simple or complex sugars, to
28 g per day in the first 2 weeks. This is then followed
by gradual increment up to 35 g per day to achieve
ongoing weight loss. In this diet, 68 % of calories comes
from fat, 27% from proteins and the remaining 5% from
carbohydrates.2,6
In the Atkins' Diet philosophy, extreme
carbohydrate restriction renders the body to derive

energy through oxidative catabolism of fatty acids.
Whilst this may serve the purpose of fat-burning, it
produces significant amount of ketones being excreted
by the urine, thus contributing to rapid initial weight
loss through diuresis. This encouraging initial response
may, therefore, be disguising. The high protein and fat
content of the diet is highly satiating, and the limited
food choices also reduces spontaneous food intake.
Besides that reduced carbohydrate intake plays a role
in curtailing caloric gain, ketosis was also found to
suppress appetite. These together may explain the shortterm weight reduction with Atkins' Diet.2,6
Bravata et al7 performed a systematic review from
1966 to 2003 to evaluate the effects of low-carbohydrate
diets on body weight and serum cardiovascular risk
markers. He concluded that weight loss achieved
through this dietary approach was principally associated
with decreased caloric intake and increased duration
between meals, but not with reduction of carbohydrate

Figure 2. My Pyramid: Steps to a Healthier You. The latest food pyramid suggested by the
US Department of Agriculture (USDA). The 6 panels represent a wide variety of food
groups (grains, vegetables, fruits, milk, oils, meat and beans) in a healthy diet. The running
cartoon figure on the left conveys a message of the importance of exercise. One size doesn't
fit all − this modified pyramid emphasizes a more individualized approach to improve
health by making modest changes in diet and incorporating regular physical activity into
daily living.
71
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content per se. However, the studies included in the
review had been highly heterogeneous in design,
carbohydrate and calorie content, as well as duration
between meals.
A total of four large randomized controlled trials
have compared the efficacy of a low-carbohydrate diet
with traditional low-fat diet. Stern et al8 randomized
132 obese subjects to receive either a low-carbohydrate
or a low-fat diet for 12 months. Their mean body-mass
index was 43 and they had a high prevalence of diabetes
(39%) and metabolic syndrome (43%). At 6-month, the
low-carbohydrate diet group showed greater weight loss,
higher high-density lipoprotein (HDL) cholesterol level,
lower triglyceride levels and improved insulin
sensitivity, independent of the use of hypoglycemic and
lipid-lowering medication, than the low-fat diet group.
However, the weight change difference between the two
groups became insignificant at 12-month.
Foster et al 9 randomized 63 obese men and
women to receive low-carbohydrate, high-protein, highfat diet or a low-calorie, high carbohydrate, low-fat
(conventional) diet for 12 months. Similarly, subjects
in the low-carbohydrate diet lost more weight (~4%)
than the low-fat group up to 6-month, and but the
difference again became insignificant by 12-month.
Throughout the course of the study, the lowcarbohydrate group had lower triglycerides and higher
HDL cholesterol than the low-calorie group. In this
study, the adherence and attrition rate were high in both
groups.
Brehm et al10 assigned 53 healthy, obese female
subjects to either a low-carbohydrate diet or a calorierestricted diet (30% fat) for 6 months. By 3 and 6
months, weight and body fat reduction were
significantly greater in the low-carbohydrate group,
although there was no difference observed in the two
diet groups in terms of serum lipids, fasting glucose,
insulin level and blood pressure.
Yancy et al 11 randomized 120 overweight,
hyperlipidaemic patients to receive either a lowcarbohydrate diet or low-fat diet group. Both groups
received exercise recommendation, and the lowcarbohydrate group also received additional nutritional
supplementation. At 6-month, the low-carbohydrate
group had greater weight reduction as well as larger

J HK Coll Cardiol, Vol 13

decrease in triglycerides and increase in HDL
cholesterol. The observed effect, however, was
confounded by the nutritional supplementation.
Although these four randomized studies
consistently demonstrated that low-carbohydrate diets
could achieve a greater weight loss at 6 months, the
calories intake was not controlled. Therefore, the
changes in appetite associated with low-carbohydrate
diet might affect the calorie intake and accounted for
the difference in the weight reduction. Segal-Isaacson
et al12 investigated how weight loss and metabolism are
affected by low-carbohydrate and low-fat diet when
energy and protein contents are held constant, and
dietary fat and carbohydrates are relatively adjusted. In
this study, 4 postmenopausal overweight female were
randomized in cross-over fashion to receive either a lowcarbohydrate or a low-fat diet for 6 weeks. They showed
no significant differences in weight loss, serum lipid,
insulin, and glucose between the two groups. However,
these findings need to be confirmed by future studies in
a large cohort of subjects.
In summary, low-carbohydrate diet was effective
for weight reduction in short-term, but this result was
not sustained at long-term follow-up. The initial
encouraging result of this diet often provides motivation
for adherence in some patients. Furthermore, the
potential adverse effects of low-carbohydrate diet have
not been fully evaluated. In fact, the AHA Scientific
Advisory has warned that this type of diet might cause
metabolically induced kidney and liver damage, as well
as worsening of CAD.1

Low Glycemic Index Diets
The GI is a measure of the blood glucose response
to the intake of a specified type of carbohydrate. By
obtaining the glycemic load, a product of dietary GI
and the total dietary carbohydrate, the glycemic effect
of a diet can be estimated.2 It has been proposed that
the elevated free fatty acid levels and increased hunger
caused by a high GI diet predisposes individuals to the
risk of obesity, diabetes and cardiovascular diseases.
The increased oxidative stress can lead to endothelial
damage and pro-coagulatory activity. Starch and sugars,
for instance, typical of high GI, tend to cause hyperinsulinemia and may promote the development of Type
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II diabetes.1
The South Beach Diet is a common variant of a
low-GI diet, characterized by an initial two-week of
vigorous carbohydrate restriction, and then a
maintenance phase which encourages intake of fruits,
vegetables, whole grains, polyunsaturated fats, nuts and
dairy products. Despite the similar initial carbohydrate
restriction with the Atkins' Diet, it encourages the intake
of lean protein such as fish and poultry, and allows olive
oil as a source of mono- and polyunsaturated fat. Clinical
studies have found that a low-GI diet confers to greater
weight loss than a high-GI diet, and may in addition
play a role in modulating HDL metabolism in inverse
proportions.13 Frost et al have suggested that every
15-unit increase in GI is associated with a 0.06 mmol/L
decrease in HDL cholesterol. 14 However the
confounders in these studies need to be taken into
consideration; as food preparation and variation may
change the GI, while recall bias may be present in selfreporting.

Very-low-fat Diets
By definition this allows less than 15% of total
calories from fat, 15% from protein and 70% from
carbohydrates, assuming an equal distribution of
saturated, monounsaturated and polyunsaturated fats.
There is some but inconclusive clinical evidence that a
very-low-fat diet together with intense life-style changes
including exercises may provide protection against
cardiovascular diseases, yet high self-motivation is
needed and attrition rate of the diet is a major concern.

The Mediterranean Diet
The dietary pattern of inhabitants around the
Mediterranean has been indicated to confer heart
protection. The key components of Mediterranean diet
are: 1) high consumption of fruits, vegetables, legumes
and grains; 2) foods with high mono-saturated to
saturated fats ratio; 3) moderate consumption of dairy
products and wine; 4) low consumption of meat and
meat products and 5) consumption of olive oil as the
principal source of fat.2
It is worth noting that no single aspect of the diet
has contributed to its extent of weight-losing effect and
the reduction of cardiovascular morbidities and
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mortalities. Nevertheless, omega-3 polyunsaturated fatty
acids have always been a major focus of the observed
cardioprotective benefits. The omega-3 fatty acids
encompasses a spectrum of compounds including
eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) found in fatty fish, as well as alpha-linolenic
acid (ALA) found in nuts, flaxseed and soybean oil.
They are suggested to possess anti-arrhythmic effect
which confers to their ability to reduce sudden cardiac
death.15 They may also decrease the arachidonic acid
content of cell membranes, down-regulate the gene
expression of adhesion molecules and inhibit
proinflammatory cytokine synthesis including tumour
necrosis factor-Alpha, interleukin-1 and interleukin-2.
They are also found to lower triglyceride level, inhibit
endothelial cell activation, decrease thrombotic
tendency and improve endothelial dysfunction in
diabetics.12
A systemic review of 11 cohort studies performed
by Marckmann et al in 199916 concluded an inverse
association between fish intake and coronary mortality,
which was stronger for fatal than non-fatal myocardial
infarction. It is also observed that the benefits so derived
were more significant in populations at higher risks.
Results from further prospective studies found that
consumption of 2 or more servings of fish per week
was associated with 30% lower risk of CAD in women.
There are some evidences that the use of omega3 fatty acids in the secondary prevention of cardiovascular diseases confers a benefit in the reduction of
all-cause mortality and fatal myocardial infarction. The
largest randomized, controlled trial, the GISSIPrevenzione Trial followed 11234 patients and found
that fish oil supplement of 1 g of EPA/DHA per day
reduces 20% of cardiac death, nonfatal myocardial
infarction and nonfatal stroke, with the greatest benefit
observed in sudden cardiac death (reduction by 45%).17
Previous studies supported the view that the benefits
induced by long-chain n-3 PUFA in seafood are specific
to fatal CAD, due primarily to a reduction in fatal
arrhythmias, rather than total coronary events. There is
also possibly a threshold effect. 3,17 The available
evidence, therefore, advocates the clinical and public
health recommendation for dietary intake of at least
1 fatty fish meal per week, although there are concerns
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such as the underestimated undesirable effect of
contaminant intake due to pollution.3
Mediterranean diet has been shown to be effective
in secondary prevention of acute and fatal myocardial
infarction. 18-23 The ability of Mediterranean diet to
induce weight loss, lower C-reactive protein level,
improve lipid profiles, and reduce insulin resistance and
prevalence of metabolic syndrome warrants further
research and application. The current evidence indicated
3 strategies in this diet preventing CAD:2 1) substituting
non-hydrogenated unsaturated fats for saturated and
trans-fats; 2) increasing consumption of omega-3 fatty
acids; and 3) consuming more fruits, vegetables, nuts,
and whole grains.

Dietary Approaches to Stop Hypertension
(DASH) Diet
The DASH diet is similar to the Mediterranean
diet, which emphasizes a high intake of fruits, vegetables,
low-fat fairy products, whole grains, nuts, fish, poultry,
and reduce intake of total and saturated fats. This diet is
mainly aimed for blood pressure reduction.2 DASH diet
is high in potassium, calcium, magnesium and fiber, but
not for sodium. Sacks et al24 conducted the DASHSodium Trial to evaluate the effect of different levels of
dietary sodium intake in conjunction with the DASH
diet for blood pressure reduction. A total of 412 subjects
with or without hypertension were randomly assigned
with either a control diet or the DASH diet. In each arm,
there were 3 different levels of sodium intake: high,
intermediate, and low, in which participants follow each
for 30 consecutive days in random order. The results of
this study confirmed that the DASH diet alone is able to
reduce systolic and diastolic blood pressure by
5.5 mmHg and 3.3 mmHg respectively. However, in the
control group, sodium restriction had a dose-response
relationship with reduction in blood pressure. While this
relationship persisted for the DASH diet, the magnitude
was comparatively smaller and was only significant
between the high and low, but not for intermediate
sodium group. Therefore, the DASH diet and sodium
restriction exhibits a synergistic effect in substantiating
reduction in blood pressure. In the clinical trial setting,
this diet has been applied in a very controlled setting
and its implementation in the general public should be
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supported by further studies in general population. Longterm health benefits by sodium restriction will also
depend upon the ability of people to make long-standing
dietary changes and the more widely available lowsodium food.

Nutritional Supplements in
Cardiovascular Health
Table 3 summarizes the current clinical evidences
on the use anti-oxidatant vitamin for prevention of
cardiovascular diseases. Despite all the initial
encouraging results from epidemiological observation
studies, 25-27 randomized controlled trial failed to
demonstrate any beneficial effects of these vitamins in
preventing cardiovascular diseases.33,34,40-42

Vitamin C
There have been extensive investigations,
especially experimental and epidemiological studies, on
the possible beneficial effects of vitamin C to prevent
cardiovascular diseases. Evidences also suggest that
vitamin C has a potential of lowering blood pressure
and cholesterol, as well as improving endothelial
function.
In the WHO MONICA study, 25 an inverse
relationship was observed between vitamin C plasma
level and mortality from CAD. Similarly, in the larger
scale prospective Nurses' Health Study in 1980,25 85118
female nurses had their vitamin C intake assessed with
a questionnaire and followed up for 16 years. The use
of vitamin C supplement was associated with a 27%
relative risk reduction for the development of CAD.
However, among those who did not take Vitamin C
supplements, there was no association between dietary
intake and CAD incidence. In another 5-year prospective
study of 1605 middle-aged Finnish men,26 vitamin Cdeficient individuals (defined as plasma level <11.4
umol/L) were found to have a 2.5 times relative risk of
myocardial infarction. For men with plasma level of
vitamin C greater than 11.4 umol/L, no differences in
fatal or non-fatal myocardial infarction outcomes were
observed. In the NHANES I study, 27 11,348 noninstitutionalized U.S. adults aged 25-74 years were
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Table 3. Recent major randomized controlled trials on vitamin C & E supplements in relation to cardiovascular
health
Trial
MRC/BHF
Heart
Protection
Study33
St. Francis
Heart
Study34

ASAP
Trial35

Population
20536 men & women
aged 40-80;
with coronary or other
occlusive arterial diseases
or diabetes
1005 men & women with
coronary calcium score at
or above 80th percentile

520 men & women with
serum cholesterol
>5.0 mmol/L

Intervention
600 mg vitamin E +
250 mg vitamin C
+ 20 mg beta-carotene
daily

Follow-up
5 years

Outcomes
No significant difference in all-cause or
cardiovascular mortalities, fatal or nonfatal MI, fatal or non-fatal stroke

Vitamin C 1 g +
Vitamin E 1000U +
Atorvastatin 20 mg daily
or matching placebo

Mean 4.3
years

Vitamin E 136 IU +
250 mg slow-release
vitamin C twice daily

6 years

Mean 4.5
years

↓ Serum cholesterol 26.5-30.4%
↓ LDL cholesterol 39.1-43.4%
↓ Triglycerides 11.2-17.0%
No reduction in atherosclerotic
cardiovascular disease events
Atherosclerotic progression as measure by
common carotid artery − intima-media
thickness slowed down in male with
intervention
No significant difference in cardiovascular
deaths or other outcomes

Mean 4.5
years

No significant difference in cardiovascular
or microvascular outcomes

Mean 7.0
years

No significant difference in major
cardiovascular events; treatment increases
risk for heart failure

HOPE
Study40

2545 women & 6996 men 400 IU Vitamin E or
with cardiovascular
matching placebo
diseases or diabetes
+ 10 mg ramiprilor
matching placebo
MICRO3654 diabetes patients
400 IU Vitamin E or
HOPE41
matching placebo
+ 10 mg ramiprilor
matching placebo
HOPE-TOO 3994 men & women with Vitamin E 400 IU or
Trial42
cardiovascular diseases or matching placebo
diabetes

studied and an inverse cardiovascular mortality was
observed with a vitamin C supplemental intake of more
than 50 mg daily. It was also found that leukocyte
ascorbic acid level was significantly lower in patients
with coronary atherosclerosis. The leukocyte ascorbic
acid level is a stable indicator of vitamin C store in the
body. Vita et al demonstrated that the leukocyte ascorbic
level but not the extent of atherosclerosis, was found to
be a predictor of unstable coronary syndrome.28 These
findings suggest that the beneficial effects by vitamin
C may result in part by influencing lesion activity rather
than retarding the overall disease progression.
Such beneficial effects of vitamin C is believed
to arise from its anti-oxidant properties which enhances
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the effect of endothelium-derived nitric oxide by
blocking oxidants such as superoxide and oxidized lowdensity lipoprotein (LDL), and thus sparing intracellular
glutathione and regenerating vitamin E. This mechanism
was supported in a study by Kugiyama et al29 who found
that intracoronary vitamin C infusion restored
angiographically proven coronary spasm induced by
acetylcholine infusion and reduced thiobarbituric
substances. Nevertheless, pathways beyond inhibiting
LDL oxidation also deserves further exploration, which
essentially include effects of reduced formation of
reactive oxygen species, improved vascular tissue
integrity, reduced leukocyte adhesion and platelet
aggregation, and enhancement of vascular relaxation
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ability.30
Despite theoretical plausibility, results from
related clinical trials remained conflicting. A recent
randomized controlled trial on 30 subjects undergoing
cardiac catheterization for evaluation of CAD by Kinlay
et al 31 had found no significant improvement on
endothelial vasomotor function after 6 months oral
administration of vitamins C and E. There is, however,
evidence that vitamin C was able to selectively improve
large artery compliance in postmenopausal women.32
The effects of vitamin C supplementation on heart
disease prevention as observed from more recent, largerscaled clinical trials have not been encouraging. In the
MRC/BHF Heart Protection Study, 20536 high risk
individuals with either CAD or other occlusive arterial
diseases, or diabetes, were randomly allocated to receive
combined 600 mg vitamin E, 250 mg vitamin C and
20 mg beta-carotene daily or matching placebo. After a
mean treatment period of 5 years, despite a substantial
increase in serum vitamin concentrations, there were
no significant differences in all-cause mortality, deaths
due to vascular or non-vascular causes, and fatal or nonfatal myocardial infarction compared to placebo.33
In the St. Francis Heart Study Randomized
Clinical Trial,34 1005 subjects with coronary calcium
scores at or above the 80th percentile for age and gender
were treated with alpha-tocopherol, vitamin C and low
doses of atorvastatin. After a mean treatment period of
4.3 years, no change was observed in the progression
of coronary calcification and there was no significant
reduction in atherosclerotic cardiovascular disease
events.
One of the major limitations of these studies is
the difficulty to isolate the effect of vitamin C from coadministered supplements, such as vitamin E. The
apparently inconsistent findings from clinical trials and
epidemiological studies may also be explained by some
possible confounding factors. The recent British
women's Heart and Health Study36 suggests that vitamin
C intake was not associated with CAD risk once life
course socioeconomic position was taken into
consideration. It has been argued that vitamin C intake
is truly associated with socioeconomic position and
previous positive epidemiological findings may have
just been a failure of recognizing confounders.
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Publication bias is another important factor to consider.
Thus further studies must be conducted before such
supplementation can be advised.
Nevertheless, on the ground of conflicting
evidence, it is appropriate to stay conservative in using
vitamin C as a supplement to protect against
cardiovascular diseases. In general, increasing intake
of fresh citrus fruits is advisable because they also
contain fibres and other essential nutrients.

Vitamin E
Among the various forms of vitamin E, alphatocopherol represents the most biologically important
form, which is predominantly found inside the LDL
particles. As a result of its antioxidant properties,
vitamin E is believed to reduce Apo B and LDL
susceptibility to peroxidation by free radicals. In patients
with CAD, it was demonstrated that LDL susceptibility
to oxidation was reduced by a combination of vitamins
E, C and beta-carotene. It was also reported from
a randomized controlled trial that vitamin E
supplementation alone was able to reduce lipid
peroxidation in vivo.37 Multiple epidemiological studies
suggested that vitamin E intake was associated with a
lower risk of CAD. For instance, the Nurses Health
Study (1980) has found a 41% risk reduction for CAD
in nonsmokers with a supplement of 100 IU Vitamin E
daily for more than 2 years.38 The Cambridge Heart
Antioxidant Study Trial also demonstrated a 77%
reduction of nonfatal myocardial infarction by treatment
with alpha-tocopherol.39
The role of vitamin E for patients with high risk
of CAD has recently been addressed. In the Heart
Outcomes Prevention Evaluation (HOPE) Study,40 2545
women and 6996 men aged 55 or above with
cardiovascular diseases or diabetes were randomly
assigned to receive either a 400 IU of vitamin E daily
or matching placebo and either ramipril or matching
placebo. After a mean of 4.5 years, there were no
significant differences in the number of cardiovascular
deaths and the incidence of secondary cardiovascular
outcomes including unstable angina, congestive heart
failure, revascularization, limb amputation and diabetic
complications. In a sub-study of HOPE-the
Microalbuminuria Cardiovascular Renal Outcomes
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(MICRO-HOPE) study,41 which evaluated the impact
of vitamin E on cardiovascular and microvascular
outcomes in 3654 diabetes patients, there was also no
beneficial effect on cardiovascular or renal outcomes
by vitamin E supplement could be found. The HOPE
study has been further extended for 4 years from 1999
to 2003 to observe the long-term effects of vitamin E
supplementation. Again, it was found that vitamin E
did not prevent major cardiovascular events or cancer,
and might even increase the risk for heart failure.42 Thus,
there is currently no indication to use vitamin E
supplements for prevention of cardiovascular diseases.

Vitamin B and Folate
The proposed mechanisms through which
vitamin B might lower cardiovascular risks stems from
the link between atherosclerosis and homocysteine, the
later being an amino acid normally found in blood from
catabolism of dietary proteins. Elevated serum
homocysteine in conditions such as cystathionine beta
synthetase deficiency, are associated with accelerated
atherosclerosis and increased mortality risk from
cardiovascular diseases. However, there is no definitive
link proven between reduction of homocysteine levels
and prevention of CAD, or any evidence that vitamin B
and folate supplementation could reduce the incidence
of CAD.
Recently, the Norwegian Vitamin Trial
(NORVIT)43 was presented at the European Society of
Cardiology Congress 2005 and reported that vitamin B
and folic acid offer no secondary protection against
cardiovascular diseases. In NORVIT, 3,749 patients who
had acute myocardial infarction within the previous
7 days were assigned to take B vitamins or placebo for
more than 3 years in addition to the standard
management. There were 4 treatment groups: 0.8 mg
folic acid per day, 40 mg vitamin B-6 per day, both
folic acid and 40 mg vitamin B-6 per day, or placebo.
After 3.5 years, there were no significant differences in
non-fatal/fatal myocardial infarction and non-fatal/fatal
stroke between groups taking vitamin B-6, folic acid
and placebo, despite the fact that homocysteine levels
were lowered by up to 30 per cent. However, the risk of
myocardial infarction and stroke was increased by 20%
in the group where folic acid and vitamin B-6 were co-
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administered. This implies that high doses of vitamin
B are ineffective for secondary cardiac prevention, and
that the combination of folic acid and B6 may actually
increase cardiovascular risk. Therefore, routine
supplementation with the B vitamins should not be
advocated for cardiovascular disease prevention.

N-3 Polyunsaturated Fatty Acids
This was discussed in the foregoing in
conjunction with the Mediterranean diet. The major
mechanism of the benefit of polyunsaturated fatty acids
is its effect on increasing omega-3 fatty acid in the cell
membrane. This leads to altered cardiac ion channel
function and reduces ventricular vulnerability to
ventricular fibrillation.3 It is noted that in the Diet and
Reinfarction Trial (DART),21 patients consuming fatty
fish had better survival despite indistinguishable
reinfarction rates from the control group. The lower
mortality could therefore be possibly explained by a
decrease in sudden cardiac death elicited by ventricular
tachyarrhythmias.44 Mozaffarian et al45 analyzed 30
randomized, double-blind, placebo-controlled trials on
the effect of fish oil on heart rate in a meta-analysis. It
was found in the overall pooled estimate that fish oil
decreased heart rate by 1.6 beats per minutes as
compared to placebo. In particular, such effect was only
evident in trials where the baseline median heart rate
was greater than or equal to 69 beats per minutes,
represented by a respective reduction of 2.5 beats per
minutes. Similarly, a significant heart rate reduction was
observed exclusively in trials with a minimum duration
of 12 weeks. Thus fish oil reduced heart rate particularly
with higher baseline heart rate or longer duration of
intervention. It should be further noted that any heart
rate reduction on fish oil intake was not related to the
fish oil dosage. The findings from the study reinforce
the hypothesis that cardiac electrophysiology is either
directly or indirectly influenced by fish oil consumption.
Given that a higher heart rate is reported to be a major
risk factor for sudden cardiac death,46-50 the heart rate
reduction concerned here may in part account for the
observed inverse relationship between fish oil intake
and fatal arrhythmias.15,51 The stronger reduction in trials
of longer duration may simply reflect the time needed
for the omega-3 fatty acids to be incorporated into the
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cellular structures. Alternatively, it is also possible that
omega-3 fatty acids favorably influence heart rate
variability and autonomic tone. Other than these stated
potential mechanisms, omega-3 fatty acid is also
proposed to result in a reduced systemic vascular
resistance, which lowers blood pressure45,52 and left
ventricular afterload, hence improving diastolic
function. The reduced heart rate can therefore be an
indirect result of enhanced ventricular efficiency.
Nonetheless, the approximately 5% lower risk of sudden
death corresponding to the 1.6 beats per minutes heart
rate reduction50 cannot explain fully the results from
the majority of previous studies, and thus further
investigation of other cardioprotective roles played by
omega-3 fatty acids is warranted.
Clinical trials of omega-3 fatty acids so far mainly
focused on its use in patients with established CAD. Its
exploration in retarding restenosis53,54 after percutaneous
coronary intervention has become less meaningful since
the introduction of effective drug-eluting stents, and its
indications in improving reocclusion rate44 in coronary
bypass grafting is currently insufficient. Therefore its
major documented benefits still rest on patients after

myocardial infarction. Although the benefits obtained
is comparable to that seen after treatment with statins,44
caution should be adopted in such interpretation by
realizing the uncertainties in dietary trials including
potentially unaccounted dietary and lifestyle changes.
On the other hand, little has been concluded about its
use in the primary prevention. Currently a large
randomized controlled trial is being conducted in
Japan, 55 in which 15000 hypercholesterolaemic
subjects free of CAD are randomly given a statin or a
statin plus 1.8 g of purified EPA and DHA. The primary
endpoint will be the number of major coronary events.
It is expected that by the end of this year the trial will
be complete and help us understand more the role of
omega-3 fatty acids in the primary prevention of CAD.

Phytoestrogens
Phytoestrogens are a diverse group of compounds
found in various plant-derived foods and beverages,
exhibiting both oestrogenic and antioestrogenic
activities. There are 3 main categories of phytoestrogens,
namely isoflavones, lignans, and coumestans (Figure 3).
The isoflavones are abundant in soybeans, chick peas,

Figure 3. Structure of phytoestrogen molecules: 1: Isoflavones (a. genistein ; b. daidzein) and
2: Lignans. The molecular structure of phytoestrogen resembles that of endogenous estradiol,
accounting for its partial estrogen-mimicking biological properties. Its biological activities in vivo,
however, are more versatile than simply estrogenic and anti-estrogenic activities. Its anti-oxidant
and other properties have yet to be further elucidated.
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clovers and other legumes. Lignans are present as a
significant ingredient in cereals and oilseeds such as
flaxseed, while coumestans are found in alfalfa and
various beans. Among all, isoflavones constitute the
most common and available form of phytoestrogen, and
of which the 2 most abundant active components being
genistein and daidzein. Because of their resemblance
to estradiol in structure and function, they appear to
exhibit selective estrogenic actions i.e. proestrogenic
responses is observed in some tissues while estrogen
inhibitory responses in others. The antiestrogenic effects
may be due to competitive inhibition at the estrogen
receptor, interference with gonadotrophins, inhibition
of estrogen synthesis or increased synthesis of estrogen
binding proteins.56-58
A major dietary source of phytoestrogen is soy,
including various forms of food such as soybeans, tofu
and soy milk. The concentration of genistein in most
soy food materials is about 1 to 2 mg per gram of protein.
There is a marked difference in the daily intake of
phytoestrogen in Asians as compared to Western
population. The typical intake value in many Asian
populations with low rates of breast and prostate cancer
is 20 to 8 mg per person per day, in contrast to only 1 to
3 mg per person per day in United State.56
Isoflavones by themselves are inactive. Its
absorption and subsequent action depends on initial
conversion by intestinal flora. After absorption, the

isoflavones are reconjugated and excreted unchanged
in the urine. This allows the body level to be estimated
by bioassay either in the serum or urine. Although
dietary phytoestrogen metabolism is significantly
influenced by intestinal flora, antibiotic use or bowel
pathology, measurement of the serum or urinary
concentration of its metabolites still serves as a valid
means of intake estimation in the population. Most
isoflavones are excreted within 48 hours after ingestion
and urinary level of isoflavonoids is a good indicator of
short-term soy food intake. From a study addressing
the correlation of soy food consumption and overnight
urinary excretion of isoflavonoids among Chinese
women in Shanghai, the urinary assessment correlated
well with the soy food intake assessment by food
frequency questionnaire not only at the group level but
also at the individual level.59
Epidemiological studies observed that the
incidence of cardiovascular diseases is markedly lower
in Asian populations, 57,60 in whom phytoestrogen
consumption is abundant. Indeed, not only are
cardiovascular diseases but some other diseases
including breast cancer, prostate cancer and colorectal
cancer also exhibiting similar distribution patterns. The
available evidences, collectively from basic science,
animal and human research studies, are summarized in
Table 4. It is believed that the observed protective effects
of phytoestrogen against various diseases share major

Table 4. Potential effects of phytoestrogens observed in preclinical and clinical studies
Preclinical
↓ Cholesterol
↓ LDL Oxidation
↑ Antioxidant enzymes
↓ Atherosclerotic lesions
↑ Vascular reactivity
↓ Platelet aggregation
↓ ICAM-1 & VCAM-1 expression
↓ Angiogenesis
↓ Neoplastic proliferation
↓ Bone loss
↓ Ventricular remodellation

Clinical
↓ Cholesterol
↓ LDL oxidation
↓ Perimenopausal hot flushes
↓ Cancer incidence
↑ Bone mineral density
↑ Vascular function
↓ Blood pressure
Side effects observed:
↑ Breast secretions
↑ Breast epithelium proliferation
↑ Endometrial proliferation

Adapted and modified from Lissin et al.58
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pathways as anti-oxidant, anti-angiogenic properties as
well as hormonal regulatory properties possessed by
the molecule.
A large number of studies had been conducted to
investigate the effect of dietary soy protein on the lipid
profile (Table 5). Meta-analysis of these studies
concluded that a mean intake of 47 g of soy protein daily
was associated with a reduction in total plasma
cholesterol of 9%, in LDL-C of 13% and in triglycerides
of 10%.61 However, the reduction in cholesterol was
directly related to the initial cholesterol level, and no
significant change was observed if the initial level was
low. The Soy Health Effect Study (SHE) also showed
that women with a higher genistein intake had a
significantly reduced waist circumference with improved
fasting insulin and an increased HDL-C level.56
Three mechanisms have been proposed to explain
for the hypocholesterolaemic effects of phytoestrogen:
1) stimulates bile secretion and therefore indirectly
enhances removal of LDL; 2) phytoestrogen intake
induces a free thyroxine surge and thereby a
hyperthyroid state which alters the lipid profile; and
3) altered hepatic metabolism with augmented LDL-C
and VLDL-C removal by hepatocytes, and such removal
stimulates the clearance of cholesterol by upregulating
LDL receptors and hence increasing LDL receptor
sensitivity. An interesting evidence for the last proposed
mechanism arises from an experiment in which LDLreceptor deficient mice have no observed benefit of
isoflavone-rich diet intake when simultaneously fed
with cholesterol-rich diet, as opposed to the normal mice
in which the isoflavone-rich diet exerts a counteracting
effect on the high cholesterol intake.56
Nonetheless, whether the hypocholesterolaemic
effect is possessed by phytoestrogen or other
components present in soy protein remain unclear.
Meta-analysis on studies specifically investigated the
effect of soy-associated isoflavones on cholesterol
concentrations have concluded that isoflavone
consumption is not related to LDL or HDL cholesterol
changes.62 It is, therefore, possible that the observed
hypocholesterolaemic effect related to soy should be
accounted by another component.
It is well known that atherosclerosis is initiated
by monocytes binding to the endothelium and migrating
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into the intimal layer to develop into foam cells. The
adhesiveness of the endothelial cells is caused by the
lipid-induced, oxidant-sensitive transcription of
adhesion molecules and chemokines, which stimulates
monocyte binding. Since oxidative modification of LDL
plays a role in the initial process of atherogenesis,
phytoestrogen, by modification of the oxidative process
may prevent subsequent parts of pathogenesis. 37,39
Clinical studies have shown that consumption of soyderived isoflavones by healthy individuals for 2 weeks
resulted in an increased oxidation resistance of LDL.63
Interestingly, the LDL particles isolated from these
subjects contained considerable amounts of isoflavones,
thus implying alteration of the LDL particles.
Furthermore, a biomarker of in vivo lipid peroxidation,
8-epi-prostaglandin F2a was also significantly lowered
in plasma by the intake of diets high in isoflavones.64
Genistein has been found to exhibit antiproliferative effects in human cell lines and being
capable of inhibiting expression of intracellular
adhesion molecule (ICAM)-1 and vascular cell adhesion
molecule (VCAM)-1 on human endothelial cells. In
addition to being a specific inhibitor of tyrosine kinase,
genistein also was found to prevent in vivo
thrombogenesis and suppress in vitro platelet
aggregation in mice.56,58
Preclinical studies in non-human primates have
showed that vascular reactivity was favorably influenced
by phytoestrogens. There is also observation that
genistein and daidzein relax mesenteric arterial rings
of rats in a dose-dependent manner.10,56 There are several
clinical studies in humans to investigate the effect of
phytoestrogens on endothelial function, however, these
studies are limited by small study population and only
performed in postmenopausal women.65-70
Recently there has been further vigorous
discussion on the validity of a cardioprotective role
claimed by dietary phytoestrogen. Van der Schouw et
al76 prospectively studied 16165 Dutch women aged
between 49 to 70 years old for a median period of 75
months. The results of this study have shown that neither
isoflavones nor lignans were associated with decreased
cardiovascular risk, although the risk is decreased with
increasing lignan intake for ever smokers. However, one
major limitation of this study was the generally low
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Table 5. Randomized controlled trials of soy protein & phytoestrogen in relation to cardiovascular health
Reference
Simons
et al 200065

Population
Cross-over study in 20
healthy postmenopausal
women

Intervention
80 mg isoflavones or
placebo daily

Duration
8 weeks

Outcomesa
→ Blood pressure
→ Plasma lipids
→ FMD

Hermansen
et al 200171

Cross-over study in 20
type II diabetic patients

50 g soy protein
(165 mg isoflavones)
or placebo
(50 g casein)

6 weeks

↓ LDL cholesterol
↓ Apolipoprotein B100
↓ Triglycerides
↓ Homocysteine
→ HDL cholesterol
→ Blood pressure

Teede et al
200166

Parallel study in 213 healthy
men & postmenopausal
women

40 g soy protein &
118 mg isoflavones
or casein placebo

3 months

Lichtenstein
et al 200272

Cross-over study in 42
subjects aged above 50 years
with LDL-cholesterol
>3.36 mmol/L

Dewell et al
200273

Parallel study in 36
moderately
hypercholesterolaemic
postmenopausal women

Four experimental
6 weeks
diets: soy protein
depleted or enriched
in isoflavones (50 mg/
4.2MJ), animal protein
with or without added
isoflavones; daily
150 mg
6 months
phytoestrogenor
placebo daily

↓ LDL/HDL ratio
↓ Triglycerides
Adverse effects:
↑ Lp(a) lipoprotein
↓ FMD
Soy protein:
↓ Total & LDL cholesterol level in
patients with ≥4.14 mmol/L
Isoflavone:
No significant effect observed

Squadrito et al
200367

Parallel study in 79 healthy
postmenopausal women

Estrogen/progestin,
or genistein 54 mg
or placebo daily

1 year

↑ Nitrate/nitrite level
↓ Endothelin-1
↑ FMD 5.5%

Teede et al
200374

Cross-over study in 46
healthy men & 34 women

80 mg isoflavones
enriched in biochanin
or formononetin,
or placebo

6 weeks

↑ Systemic arterial compliance
↓ cPWV
→ FMD
→ Blood pressure

Steinberg et al
200368

Cross-over study in 28
postmenopausal women

Three 25 g protein
products respectively
with 107, 2 and 0 mg
total isoflavones daily

6 weeks

↑ FMD
→ Endothelial markers

Lissin et al
200469

Parallel study in 40
postmenopausal women

90 mg isoflavones
or placebo daily

6 weeks

KreijkampKaspers et al
200570

Parallel study in 202
postmenopausal women
aged 60-75

Soy protein containing 1 year
99 mg isoflavones or
milk protein placebo
daily

↑ Vascular reactivity to nitrogycerine
→ FMD
→ Lipid profile
Equol producers:
↓ Blood pressure
↑ Endothelial function
Equol nonproducers:
↑ Blood pressure
↓ Endothelial function

He et al
200575

Parallel study in 302 Chinese Soybean cookies
12 weeks
adults aged between 35 to 64 containing 40g of
either soybean protein
or complex
carbohydrate daily

a

→ Lipid profile

↓ 3 to 4 mmHg systolic & diastolic
blood pressure

FMD: Flow-mediated dilatation; cPWV: Central pulse wave velocity.
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intake of isoflavones in the population.77 The median
daily intake of isoflavones was only 0.369 mg. Even in
the 4th quartile, the total daily isoflavone intake was
only 0.541 mg, which is significantly lower than in the
Asian populations. It is possible that the intake is too
low to exert a significant protective effect. The study
also did not provide a serum or urine quantification of
phytoestrogen level to confirm the dietary intake.
Therefore we should be cautious on such interpretation.
Further prospective randomized controlled trials studies
are needed to provide further verification.

Conclusions
Epidemiological observation studies on selected
dietary approaches, such as the Mediterranean diet, have
been shown to be associated with a reduced incidence
of CAD. However, very limited clinical evidences are
available to support their use for primary prevention of
cardiovascular diseases. Among these dietary
approaches, only Mediterranean diet has been
demonstrated to be effective for secondary prevention
of cardiovascular diseases. Related clinical trials on diet
conducted so far are limited by uncontrolled caloric
intake and concurrent changes in alternative food
consumption. Before further studies are performed to
give more informative guidance, a diet rich in fresh fruits
and vegetables but restricted for high GI carbohydrates,
with polyunsaturated fat intake from plant oil and fish
is generally advisable and mostly consistent with the
current evidence for heart health. An individualized
approach and the importance of holistic lifestyle
commitments including regular exercise should be
emphasized.
Most nutritional supplements, on the other hand,
either prove inefficacious in conferring cardiovascular
benefits, or that the efficacy is conflicting. Some of them
may actually be harmful if taken regularly. Physicians
should therefore be cautious in advising on and
prescribing these supplements. Phytoestrogen, for
instance, represents a recently focused branch of
nutritional substances with potentially cardioprotective
implications. Ample supportive experimental data exist
but clinical studies are negative in general. Its

J HK Coll Cardiol, Vol 13

recommendations will depend upon further randomized
controlled trials.
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